Corbus Pharmaceuticals
在场
高管
查看带有其 12 名主要高管的组织结构图
Corbus Pharmaceuticals 搜索最多的简介
- Yuval Cohen, Chief Executive Officer and Director
- Alan Holmer, Chairman of the Board
- Yong Ben, Director
高管在Corbus Pharmaceuticals变化
- Winston Kung已作为Director加入公司 (新闻发布的2024八月21号).
- Dominic Smethurst已作为Chief Medical Officer加入公司 (新闻发布的2024三月1号).
创建提醒
跟踪 Corbus Pharmaceuticals 的高管变动
药店
Corbus Pharmaceuticals 拥有 1,835 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。
Popular M&A news in 药店
- Grace Therapeutics将在Oct 24, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
- Orasis Pharmaceuticals 刚刚宣布为 78 筹款数百万美元。 (公布2024十月21号).
- Lundbeck has announced the acquisition of Longboard Pharmaceuticals (公布2024十月17号).
药店 行业的其他推荐联系人
消息
Corbus Pharmaceuticals 的最新新闻稿
- Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference
- Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)
- Corbus Pharmaceuticals to Participate in the BMO Capital Markets’ Oncology Summit
- Corbus Pharmaceuticals Strengthens Board of Directors with Appointment of Winston Kung
- Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in August
- Corbus Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
- SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in Patients with Nectin-4 Positive Tumors in a Clinical Update Presented at ASCO 2024
- Updated Phase 1 Clinical Data for SYS-6002 (CRB-701) to be presented at 2024 ASCO Annual Meeting
- Corbus Pharmaceuticals to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
- Corbus Pharmaceuticals to Participate in the BTIG Obesity Health Forum
- View more press releases Close
通过电子邮件
